Journal article

Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Ye, W., Olsson-Brown, A., Watson, R. A., Cheung, V. T. F., Morgan, R. D., Nassiri, I., Cooper, R., Taylor, C. A., Akbani, U., Brain, O., Matin, R. N., Coupe, N., Middleton, M. R., Coles, M., Sacco, J. J., Payne, M. J., & Fairfax, B. P. (2021). Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. British Journal of Cancer, 124(10), 1661–1669.

MLA Style

Ye, W, et al. “Checkpoint-Blocker-Induced Autoimmunity Is Associated with Favourable Outcome in Metastatic Melanoma and Distinct T-Cell Expression Profiles.” British Journal of Cancer, vol. 124, no. 10, 2021, pp. 1661–69.

Chicago Style

Ye, W, A Olsson-Brown, RA Watson, et al. 2021. “Checkpoint-Blocker-Induced Autoimmunity Is Associated with Favourable Outcome in Metastatic Melanoma and Distinct T-Cell Expression Profiles.” British Journal of Cancer 124 (10): 1661–69.
Print

Access Document

Files:: Ye_et_al_2021_Checkpoint-blocker-induced_autoimmunity_is.pdf

(Preview, Version of record, pdf, 960.5KB, Terms of use)

Publisher copy:: 10.1038/s41416-021-01310-3

Authors

+ Ye, W More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0002-8983-0355

+ Olsson-Brown, A More by this author

Role:: Author
ORCID:: 0000-0001-7721-5817

+ Watson, RA More by this author

Role:: Author
ORCID:: 0000-0002-8838-9406

+ Cheung, VTF More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0003-1715-2281

+ Morgan, RD More by this author

Role:: Author
ORCID:: 0000-0003-0612-0954

More authors...

+ Medical Research Council More from this funder

Funder identifier:: https://ror.org/03x94j517
Grant:: MR/N025989/1

+ National Institute for Health and Care Research More from this funder

Publisher:: Springer Nature [academic journals on nature.com]
Journal:: British Journal of Cancer More from this journal
Volume:: 124
Issue:: 10
Pages:: 1661-1669
Publication date:: 2021-03-15
DOI:: 10.1038/s41416-021-01310-3
EISSN:: 1532-1827
ISSN:: 0007-0920

Language:: English
Keywords:: CD8

Ipilimumab

Melanoma

Oncology

Medicine

Immunology

Cancer

Cancer research

Immunotherapy

Immune checkpoint

Adverse effect

Blockade

Nivolumab

Immune system

Pembrolizumab

Internal medicine

Receptor
Pubs id:: 1168401
Local pid:: pubs:1168401
Source identifiers:: W3137229530
Deposit date:: 2025-11-13
ARK identifier:: ark:/29072/ora_f0dc145b0429431cb53f070618f975e4

Terms of use

Copyright date:: 2021

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP